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have benefitted greatly from these interactions.   Results of our 
collaboration can be seen in the ROSIS project and associated short 
courses, involvement in clinical audit as members of the 
multidisciplinary team and several joint publications.  It is a great 
honour to receive this award and I am delighted to ‘finally’ be a 
physicist albeit it an honorary one – but maybe that is even better! 
 
 AWARD LECTURE: COMPANY AWARD LECTURES  
  
OC-0285   
Motion simulations with a statistical deformation model to evaluate 
PTV margins in locally advanced prostate cancer 
S. Thörnqvist1, L.B. Hysing2, A.G. Zolnay3, M. Söhn4, M.S. Hoogeman3, 
L.P. Muren1, L. Bentzen5, B.J.M. Heijmen3 
1Aarhus University Hospital, Department of Oncology and Medical 
Physics, Aarhus, Denmark  
2Haukeland University Hospital, Department of Medical Physics, 
Bergen, Norway  
3Erasmus MC Daniel den Hoed Cancer Center, Department of 
Radiation Oncology, Rotterdam, The Netherlands  
4University Hospital Grosshadern LMU München, Department of 
Radiation Oncology, München, Germany  
5Aarhus University Hospital, Department of Oncology, Aarhus, 
Denmark  
 
Purpose/Objective: Radiotherapy of several major tumour sites 
involves simultaneous treatment of multiple targets, typically 
occurring when irradiation of both the primary and elective targets is 
indicated. In the treatment of locally advanced prostate cancer, the 
dominating residual geometrical uncertainties following image-
guidance can be ascribed to deformations and uncorrelated motion of 
the involved targets: the prostate (CTV-p), the seminal vesicles (CTV-
sv) and the pelvic lymph nodes (CTV-ln). The aim of this study was to 
use a statistical deformation motion model to simulate target motion 
throughout a course of treatment in this clinical scenario, for the 
purpose of margin evaluations. 
Materials and Methods: The study was based on target delineations 
for 19 patients, all with a CT-set consisting of one planning and 9-10 
repeat CTs. After rigidly aligning the repeat CTs to the planning CT 
based on intra-prostatic markers, the displacement vectors between 
the target shapes in the planning CT and those in the repeat CTs were 
calculated with deformable registration. For each patient, a motion 
model based on principal component analysis (PCA) of these 
displacement vectors was created. From this model statistical 
meaningful inter- and extrapolations of the delineated target shapes 
were made to construct new target shapes according to their 
probabilities of occurrence and without prior assumptions of the 
relative importance of the different motion and deformation patterns. 
Maximally conformal synthetic dose distributions were created for 
various uniform CTV-to-PTV expansions in the planning CT. For each 
patient, the motion model was employed to analyse target coverage 
distributions for 1000 simulated treatment courses on each of these 
synthetic dose distributions. 
Results: Simulations of inter-fractional motion resulted in 7,10 and 18 
patients with an estimated average accumulated dose of at least 95% 
of the prescribed dose to 99% of the CTV (D99), for uniform margins 
around the prostate of 3mm, 4mm and 5mm, respectively. For the 
seminal vesicles and the pelvic lymph nodes, margin expansion of 
3mm, 5mm, 7mm, 9mm resulted in 1, 11, 15, 16 and 8, 18, 18, 18 
patients respectively with an expected average D99> 95% of the 
prescription. In Figure 1, the estimated average D99 including the10%-
90%-percentiles for each target are shown. 
 
 
Conclusions: We have developed a deformable registration based 
motion simulation model and successfully applied this on a 
comprehensive repeat CT data-set. For the patients included in this 
study, 90% had full target coverage with CTV-to-PTV expansions of 
5mm for the prostate, 11mm for the seminal vesicles and 5mm for the 
pelvic lymph nodes.  
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Purpose/Objective: Respiratory motion introduces complex spatio-
temporal variations in the dosimetry of radiotherapy and may 
contribute to uncertainties in radiotherapy planning. This novel in 
vitro study investigates the potential radiobiological implications 
occurring due to tumour motion in lung cancer radiotherapy. 
Materials and Methods: A bespoke phantom and motor-driven 
platform to replicate respiratory motion and study the consequences 
on tumour cell survival in vitro was constructed. Human non-small cell 
lung cancer cell lines (H460 and H1299) were irradiated in uniform (0-
8Gy) and modulated radiotherapy fields (4Gy) in the presence and 
absence of respiratory motion (14 and 21 respirations/minute). 
Clonogenic survival was calculated for irradiated and shielded regions. 
Direction of motion, replication of dosimetry by MLC manipulation and 
oscillating lead shielding were investigated to confirm differences. 
Differences were compared using the Mann-Whitney test. 
Results: No difference in survival was seen for cell lines uniformly 
irradiated with or without motion. With respiratory motion survival 
was significantly higher for out-of-field regions for H460 and H1299 
compared with static irradiation of 50% of the flask (p<0.0005). 
Significantly higher survival was found in the in-field region for the 
H460 cell line (p<0.03). Oscillating lead shielding also produced these 
significant differences. MLC and perpendicular motion had no 
significant difference compared to static irradiations. 
Conclusions: These data indicate that respiratory motion can impact 
on in- and out-of-field survival in the presence of non-uniform 
irradiation for lung cancer cell lines. This may have implications for 
the efficacy of radiotherapy particularly in areas where tumour is 
missed due to respiratory motion. 
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Purpose/Objective: Rotational IMRT (rIMRT, tradenames VMAT(R), 
RapidArc(R)) has set new standards for the speed of treatment 
delivery. However, today's treatment machines are not optimized for 
this kind of delivery, with the consequence that design constraints on 
leaf and gantry rotation speeds and dose rates limit the achievable 
treatment times. Here, we explore the questions of how a specialized 
linac for rIMRT would have to be designed, and which treatment times 
are ideally achievable without loss of plan quality, relative to the best 
dose distributions achievable today. 
Materials and Methods: The fundamental design of the hypothetical 
linac comprises: a continuously rotating gantry with a cone beam and 
a conventional MLC, a continuously variable dose rate with 
instantaneous beam switching, and a fixed patient position. Variable 
parameters were leaf and gantry rotation speed as well as maximum 
and minimum dose rate. The linac was modelled in a research version 
of a commercial TPS, being capable of rIMRT planning including 
segment shape optimization (direct aperture optimization). The leaf 
sequencing algorithm was specifically developed for this virtual linac, 
and determines the optimum leaf trajectories from the minimization 
of a complex cost function which comprises the input from multiple 
gantry angles simultaneously. It also finds the required number of full 
rotations. Planning studies were performed on cases of variable 
complexity to determine the combination of leaf and gantry speed 
which allows for the shortest delivery times. 
Results: There appear to be two fundamentally different paths 
towards fast delivery times: for a slow moving gantry, fast leaves are 
obviously an advantage to increase the modulation per sector of the 
gantry rotation, because treatments with few full rotations are 
favoured. The other mode is an extremely fast rotating gantry (10-20 
RPM), combined with a larger number of rotations and relatively low 
modulation per sector of the gantry rotation. Modulation is then 
achieved by multiple passes of the beam over the same sector. Both 
methods are capable of delivering the high quality of treatment plan 
possible with a modern state-of-the-art linac (reference plans were 2-
arc plans for Varian TrueBeam(R) and Elekta Agility(R) linacs). Lower 
treatment times were achievable with the fast gantry rotation. The 
minimum was obtained at around 20 RPM/18 seconds for prostate 
cases, and 12 RPM/45 seconds for complex head-and-neck cases with 
3 dose levels. Optimum max dose rates were 1200-1800 MU/min. Even 
faster gantry speed resulted in a greater number of beam interrupts 
and larger sectors of gantry rotation 'in the dark' and therefore more 
full rotations for realistic leaf speeds. 
Conclusions: A planning study for a hypothetical, yet realistic, 
continuously rotating linac design with a novel type of leaf sequencing 
algorithm shows, that today's quality of dose distribution can be 
achieved with delivery times in the order of 20-45 seconds.  
   
 SYMPOSIUM: DOSE-DENSITY IN LUNG CANCER  
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The advent of SBRT for lung tumors has opened new horizons in the 
curative radiotherapyf or lung cancer. In peripheral lesions, very high 
local control rates have throughout been reported after high dose 
hypofractionated radiotherapy. Besides high precision and small 
volumes, extreme treatment acceleration is a key feature for this 
success. 
Therefore it is tempting to translate the successful concept of SBRT to 
more central lesions. However, while peripheral lesions are mainly 
surrounded by lung, the normal tissue neighborhood of central lesions 
is challenging and reports of severe and fatal normal tissue toxicities 
like bleedings and necroses have caused concerns.  
On the other sides some patient cohorts with encouraging results after 
SBRT of central lesions have been observed after the use of less 
hypofractionated SBRT strategies raising the question of “overkill” by 
other dose/fractionation regimes. 
In order to approach this issue scientifically, clinical studies are 
needed to prospectively assess not only local control but also toxicity. 
Current study concepts will be discussed. 
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Experimental and clinical evidence for time-dose-fractionation in 
locally advanced non-small cell lung cancer as the basis for dose-
escalation will be reviewed and strategies to improve outcome after 
radiotherapy will be discussed. An essential component of these 
strategies represents advanced technology in planning and treatment 
delivery such as motion management, image-guidedance and 
functional imaging.  
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Optimising the management of patients with LDSCLC continues to be a 
challenge. The relevant role of radiotherapy was clearly demonstrated 
in the early 1990’s with two meta-analyses which established a 
survival benefit for patients treated with radio-chemotherapy, 
however, the optimal method of integrating thoracic radiotherapy 
(TRT) with chemotherapy remained undefined.  
To date, some topics are still controversial: the optimal timing of 
radiotherapy, the radiation dose, the fractionation and the combined 
chemotherapy regimen.  
The rationale for an early administration of radiation therapy during 
the course of chemotherapy may be to eliminate localized populations 
of chemotherapy-resistant tumour cells that might be responsible for 
treatment failure if permitted to disseminate systemically. This would 
be an obvious advantage of early administration of radiotherapy. Of 
the seven randomized controlled trials examining timing, only those 
with early chemoradiation have 5-year survival rates in excess of 20%. 
The "chemoradiation package" can be defined as the time from the 
start of chemotherapy until the completion of radiotherapy. The best 
median survival and long-term survival rates have been observed in 
trials with a chemoradiation package time of less than 6 weeks. 
Several phase III trials investigated the timing and sequencing of 
radiotherapy. Fried et al. reported a meta-analysis carried out 
regarding the timing of radiotherapy. Six out of seven randomised 
trials, with a total of 1524 patients, favoured the use of early 
radiotherapy, and the overall risk ratio at 2 years was 1,17 (95%CI 
1,02- 1,35; p=0,03) favouring the use of early radiotherapy. The 
subgroup analysis revealed that the benefit of the early radiotherapy 
schedule was seen in patients receiving hyperfractionated radiation 
and/or platinum based compared  chemotherapy (18% of absolute 
benefit).  
More recently, a significant relationship between the value of the 
time lapse from the first day of chemotherapy to the end of thoracic 
radiotherapy (SER), as well as overall survival and disease free 
survival, was reported. The analysis on 212 patients with limited stage 
SCLC shows that each day of extension of the SER resulted in 
increased probability of death (decrease of OS) by 0.28% and an 
increase of  the risk of development failure (decrease of DFS) by 
0.31%.   
Historically, total doses of 40-50 Gy delivered in 1,8-2,0 Gy daily 
fractionation have been utilized in once daily radiation schemes. 
Clinical results comparing standard fractionation (SF) with total doses 
less than 54Gy and more than 54Gy or accelerated fractionation (AHF) 
show that for the local control rates, the overall and progression-free 
survival rates, all outcomes were significantly lower in the SF <54 Gy 
group than in the other two groups, although no significant difference 
was found between the AHF and SF ≥54 Gy groups.  
With regard to fractionation, the customary once daily radiotherapy 
dose divided into two treatments each day has biologic advantages. In 
vitro, small-cell lung-cancer cell lines have marked radio-sensitivity 
even to small doses of radiation. The cornerstone trail is certainly 
Turrisi’s one, an intergroup phase III study, in which accelerated 
hyperfractionation was superior to standard fractionation. At the five 
year follow-up, the difference between the treatments favoured the 
twice-daily treatment group by 10 percent in comparison with 
standard fractionation. As expected, esophageal toxicity was 
increased (G3 27% vs 11%, respectively).  
More recently, a meta-analysis on modified fractionation on 685 
patients with a median follow-up of 12.1 years and 622 deaths was 
published. The effect of modified RT on overall survival was absolute 
benefit of 1.7% at 3 years (from 29.6% to 31.3%) and 5.1% at 5 years 
(from 18.7% to 23.8%).  
Only carefully conducted prospective clinical trials will allow us to 
further improve local control and survival rates of LD-SCLC patients in 
the future. 
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